Clinical Trial Update: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) [Phase 3]

View source ↗

Summary

This Phase 3 clinical trial update describes PEACE6-Vulnerable, a study evaluating androgen deprivation therapy with or without darolutamide in men with de novo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• NUBEQA (darolutamide) (darolutamide)

Snippet

Sponsor: UNICANCER | Conditions: Prostate Cancer Metastatic | Phase 3 | Status: RECRUITING